AKR1C2 and brain glioma: Le et al. [39] reported that AKR1C1 and AKR1C2 proteins were involved in the process of cancer cell resistance, and selective targeting of GLUT-3 in the AKR1C protein of brain glioma can delay the acquisition of drug resistance temozolomide in astrocytes.